Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved

Summary by AI BETAClose X

Novo Nordisk announced headline results from the REDEFINE 4 trial, where CagriSema demonstrated 23.0% weight loss in people with obesity after 84 weeks, but did not achieve its primary endpoint of non-inferiority compared to tirzepatide 15 mg, which achieved 25.5% weight loss. When considering treatment adherence, CagriSema resulted in 20.2% weight loss versus 23.6% for tirzepatide. The company noted CagriSema's safe and well-tolerated profile, with gastrointestinal issues being the most common adverse events. Further trials are planned to explore CagriSema's full weight loss potential with higher doses.

Disclaimer*

UK 100

Latest directors dealings